Diffuse Large B-Cell Lymphoma Clinical Trial
Official title:
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). DLBCL is also a type of cancer of the blood. They are referred to as 'relapsed' when the disease has come back after treatment and 'refractory' when treatment no longer works. The study has 2 main parts, called phase 1 and phase 1b. The main objective of both parts will be to evaluate the safety and tolerability of the study drug, called EZM0414. The main objective of phase 1b will also be to determine the effectiveness of EZM0414. During phase 1 six dose levels will be tested to obtain the most tolerated dose. Participants will receive study drug at the assigned dose level every 28 days. During phase 1b participants will receive study drug at the maximum tolerated dose in 28-day cycles.
Status | Recruiting |
Enrollment | 96 |
Est. completion date | June 27, 2025 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Voluntarily provide signed informed consent after review of verbal and written material about the trial and agree to abide with protocol requirements. All study related activities must be carried out after written consent is obtained. 2. Subjects must be =18 years of age at the time of signing the ICF (Informed Consent Form). 3. Subjects must have an Eastern Cooperative Oncology Group (ECOG) status of 0 - 2. 4. For MM, subjects must have measurable disease by IMWG (International Myeloma Working Group) 2016 criteria 5. For DLBCL, subjects must have measurable disease by Lugano criteria 6. Females must not be breastfeeding or pregnant at screening 7. Females of childbearing potential must not have had unprotected sexual intercourse while participating in this study 8. Male subjects must either practice complete abstinence or agree to use a latex or synthetic condom, even with a successful vasectomy, during study treatment and for 30 days after the final dose of study treatment Exclusion Criteria: 1. Subjects with plasma cell leukemia defined as a plasma cell count >2000/mm3. 2. Subjects with Waldenstrom's macroglobulinemia or smoldering MM. 3. Subjects who had prior treatment with SETD2 or NSD2 inhibitor. 4. Subjects with active acute or chronic systemic infection requiring systemic treatment, including COVID-19. 5. Has cardiovascular impairment 6. Prolongation of corrected QT interval using Fridericia's formula (QTcF) to > 480 msec or history of long QT syndrome. 7. Known left ventricular ejection fraction (LVEF) < 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA). 8. Prior major surgery within 4 weeks of treatment start. 9. Known hypersensitivity to components of the investigational product. 10. Subjects who have received treatment with any unapproved drug product within 4 weeks prior to screening. 11. Current participation in any other interventional clinical study except for follow up. 12. Subjects with a history of or active malignancy other than disease under study 13. Underlying medical/social conditions that in PI opinion will place the subject in significant risk and affect the interpretation of toxicity and adverse events assessments. 14. Inability to take oral medication or known gastrointestinal (GI) disease, GI procedure or medical condition that could interfere with the oral absorption or tolerance of the study drug |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Regional Cancer Care Associates LLC - Chevy Chase | Chevy Chase | Maryland |
United States | Baylor University Medical Center (Texas Oncology) | Dallas | Texas |
United States | Karmanos Cancer Institute | Detroit | Michigan |
United States | City of Hope | Duarte | California |
United States | Astera Cancer Care | East Brunswick | New Jersey |
United States | NEXT Virginia | Fairfax | Virginia |
United States | Regional Cancer Care Associates LLC - Freehold | Freehold | New Jersey |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Aurora St. Luke's Medical Center | Milwaukee | Wisconsin |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
United States | Weill Cornell Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Epizyme, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants with Adverse Events (AEs) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Through study completion, an average of 3 years | |
Primary | Percentage of participants with clinically significant changes in physical examination | Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be evaluated by the Investigator based on the CTCAE, version 5.0. | Through study completion, an average of 3 years | |
Primary | Percentage of participants with clinically significant changes in vital signs | Percentage of participants with clinically significant changes in vital signs will be reported. The clinical significance will be evaluated by the investigator based on the CTCAE, version 5.0. | Through study completion, an average of 3 years | |
Primary | Percentage of participants with clinically significant changes in 12-lead ECG readings | Percentage of participants with clinically significant changes in ECG readings will be reported. The clinical significance will be will be evaluated by the investigator based on the CTCAE, version 5.0. | Through study completion, an average of 3 years | |
Primary | Percentage of participants with clinically significant changes in laboratory parameters (hematology including coagulation profile, serum chemistries, and urinalysis) | Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will be evaluated by the Investigator based on the CTCAE, version 5.0. | Through study completion, an average of 3 years | |
Primary | Performance status evaluated by ECOG | ECOG is a 6-point performance status scale used to assess performance using participant as a key indicator (e.g., 0 = fully active, 2 = up and about more than 50% of walking hours, 5 = dead) Performance status will be assessed per usual clinical practice and will be recorded in the medical record. | Through study completion, an average of 3 years | |
Primary | Concomitant medication monitoring | Defined as any medication or vaccine, including over-the-counter or prescription medicines, vitamins, and/or herbal supplements that the participant is receiving at the time of enrollment or received during the study. | Through study completion, an average of 3 years | |
Primary | Part 1 Phase 1: Dose limiting toxicities (DLT) | Events will be assessed as DLTs according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0) | Through study completion, an average of 3 years | |
Primary | Part 2 Phase 1b: Establishing Maximum Tolerated Dose (MTD) and a recommended Phase 2 Dose (RP2D) | Recommended Phase 2 will be established by analyzing AE, clinical laboratory tests and pharmacokinetics Profile. | Through study completion, an average of 3 years | |
Primary | Part 2 Phase 1b: Objective Response Rate (ORR) | Defined as the proportion of responders as assessed by Investigator per International Myeloma Working Group (IMWG) 2016 guidelines for MM (Stringent complete response (sCR), Complete Response (CR), Very good partial response (VGPR), and Partial Response (PR)) or Lugano 2014 guidelines for Diffuse large B cell lymphoma (DLBCL) (CR+PR). | Through study completion, an average of 3 years | |
Secondary | Part 2 Phase 1b: Progression-free survival (PFS) | Defined as the time from start of treatment until the first documented PD, as assessed by Investigator per IMWG 2016 guidelines for MM or Lugano 2014 guidelines for DLBCL or death due to any cause, whichever occurs first. | Through study completion, an average of 3 years | |
Secondary | Part 2 Phase 1b: Disease Control Rate (DCR) | Defined as the proportion of subjects who have achieved confirmed CR, sCR, PR, VGPR, minimal response or stable disease (SD) per IMWG 2016 Guidelines for MM or CR, PR, or SD per Lugano 2014 Guidelines for DLBCL since administration of EZM0414 in dose expansion part (including the cycle 1 observations of the subjects who receive EZM0414 at MTD in the dose escalation part and are rolled over to the dose expansion part). | Through study completion, an average of 3 years | |
Secondary | Part 2 Phase 1b: Duration of response (DOR) | Defined as the time from initial CR or PR to documented progression or death, whichever comes first, as assessed by Investigator per IMWG 2016 guidelines for MM or Lugano 2014 guidelines for DLBCL | Through study completion, an average of 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
Recruiting |
NCT05823701 -
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
|
Phase 2 | |
Completed |
NCT01691898 -
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03656835 -
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
|
N/A | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Active, not recruiting |
NCT02060656 -
Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)
|
Phase 2 | |
Active, not recruiting |
NCT01653067 -
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
|
Phase 2 | |
Enrolling by invitation |
NCT00846157 -
Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients
|
Phase 3 | |
Completed |
NCT00440583 -
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
|
Phase 2 | |
Completed |
NCT01851551 -
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
|
Phase 1/Phase 2 | |
Recruiting |
NCT04981795 -
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
|
||
Completed |
NCT01186978 -
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
|
N/A | |
Completed |
NCT01197560 -
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03246906 -
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT05990985 -
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
|
N/A | |
Completed |
NCT02890602 -
Erythropoietin for Management of Anemia Caused by Chemotherapy
|
Phase 2 | |
Completed |
NCT03630159 -
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
|
Phase 1 | |
Active, not recruiting |
NCT04529772 -
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
|
Phase 3 | |
Active, not recruiting |
NCT02900651 -
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT02481310 -
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 |